Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled SAR439859 absorption, metabolism, and excretion study in healthy postmenopausal women
NCT04940026Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amcenestrant in breast cancer, sponsored by Sanofi. Primary endpoints: Percentage of radioactive dose excreted in urine after IV administration, Percentage of radioactive dose excreted in feces after IV administration and 24 more. Started Jun 2021; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04940026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940026.